Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cystemustine in recurrent high grade glioma.

X Durando1, E Thivat, H Roché

  • 1Centre Jean Perrin, 63011, Clermont-Ferrand Cédex, France.

Journal of Neuro-Oncology
|April 1, 2006
PubMed
Summary

Cystemustine shows promise for treating recurrent high-grade glioma. This nitrosourea demonstrated encouraging activity, with a median overall survival of 8.3 months in patients with recurrent glioma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution.

Clinical and translational radiation oncology·2024
Same author

[Frameless trigeminal neuralgia radiosurgery with a dedicated linear accelerator: From equipment commissioning to initial clinical results].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

A survey on the experience of risk-taking behaviors of bedridden patients in neurosurgery.

Neuro-Chirurgie·2023
Same author

Neural correlates of consciousness and related disorders: From phenotypic descriptors of behavioral and relative consciousness to cortico-subcortical circuitry.

Neuro-Chirurgie·2021
Same author

Functional and dysfunctional impulsivities changes after subthalamic nucleus-deep brain stimulation in Parkinson disease.

Neuro-Chirurgie·2021

Area of Science:

  • Neuro-oncology
  • Clinical Pharmacology
  • Cancer Therapeutics

Background:

  • High-grade gliomas are aggressive brain tumors with limited treatment options upon recurrence.
  • Recurrent high-grade glioma necessitates novel therapeutic strategies to improve patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of cystemustine, a nitrosourea agent, in patients with recurrent high-grade glioma.
  • To determine the overall survival and response rates associated with cystemustine treatment.

Main Methods:

  • A study involving 48 patients with recurrent high-grade glioma (glioblastomas, astrocytomas, oligodendrogliomas).
  • Patients received cystemustine (60 mg/m2) every two weeks via infusion.
  • Primary endpoint was overall survival analysis.

Related Experiment Videos

Main Results:

  • Median overall survival was 8.3 months; 6-month and 12-month survival rates were 55.3% and 29.8%, respectively.
  • Objective response rate was 18.8%, with 54.2% of patients achieving stable disease.
  • WHO performance status, histology, and response to cystemustine were significant prognostic factors.

Conclusions:

  • Cystemustine exhibits encouraging anti-tumor activity in patients with recurrent high-grade glioma.
  • The drug represents a potential therapeutic option for this challenging patient population.